This content is in French.
How can we combat chemoresistance in triple-negative breast cancer ?
27 février 2024
Chemoresistance in triple-negative breast cancer complicates patient management. In this study, researchers investigated the mechanisms behind this chemoresistance. They discovered that the protein arginine methyltransferase-1 (PRMT1)…
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Takehiro Yamamoto et al. PRMT1 sustains de novo fatty acid synthesis by methylating PHGDH to drive chemoresistance in triple-negative breast cancer. Cancer Res. 2024 Feb 22.
View the source
